UroGen Pharma Ltd. (URGN)
Largest Insider Buys in Sector
URGN Stock Price History Chart
URGN Stock Performance
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Insider Activity of UroGen Pharma Ltd.
Over the last 12 months, insiders at UroGen Pharma Ltd. have bought $0 and sold $581,248 worth of UroGen Pharma Ltd. stock.
On average, over the past 5 years, insiders at UroGen Pharma Ltd. have bought $520,273 and sold $379,445 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 160 shares for transaction amount of $2,096 was made by Schoenberg Mark (Chief Medical Officer) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, UroGen Pharma Ltd.
| 2024-06-10 | Sale | Schoenberg Mark | Chief Medical Officer | 5,153 0.0146% | $13.08 | $67,401 | +30.70% | |
| 2024-03-18 | Sale | Schoenberg Mark | Chief Medical Officer | 12,000 0.0341% | $14.05 | $168,600 | -4.90% | |
| 2024-02-01 | Sale | Schoenberg Mark | Chief Medical Officer | 3,789 0.0123% | $15.78 | $59,790 | -9.06% | |
| 2024-02-01 | Sale | Smith Jason Drew | General Counsel | 4,993 0.0162% | $15.78 | $78,790 | -9.06% | |
| 2024-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 3,789 0.0122% | $15.74 | $59,639 | -7.80% | |
| 2024-01-31 | Sale | Smith Jason Drew | General Counsel | 4,993 0.0161% | $15.74 | $78,590 | -7.80% | |
| 2023-08-31 | Sale | Smith Jason Drew | General Counsel | 3,800 0.0129% | $18.01 | $68,438 | -18.19% | |
| 2023-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 1,900 0.0079% | $10.12 | $19,228 | +14.63% | |
| 2023-01-31 | Sale | Smith Jason Drew | General Counsel | 1,636 0.0068% | $10.12 | $16,556 | +14.63% | |
| 2022-10-31 | Sale | Schoenberg Mark | Chief Medical Officer | 258 0.0011% | $11.85 | $3,057 | -12.49% | |
| 2022-08-31 | Sale | Smith Jason Drew | General Counsel | 3,606 0.0153% | $7.21 | $25,999 | +29.46% | |
| 2022-07-31 | Sale | Schoenberg Mark | Chief Medical Officer | 259 0.0011% | $7.81 | $2,023 | ||
| 2022-04-30 | Sale | Schoenberg Mark | Chief Medical Officer | 254 0.001% | $6.62 | $1,681 | ||
| 2022-01-31 | Sale | Barrett Elizabeth A. | Chief Executive Officer | 8,195 0.0356% | $7.58 | $62,118 | +5.96% | |
| 2022-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 1,374 0.006% | $7.58 | $10,415 | +5.96% | |
| 2022-01-31 | Sale | Smith Jason Drew | General Counsel | 414 0.0018% | $7.58 | $3,138 | +5.96% | |
| 2022-01-31 | Sale | Henderson Molly | Chief Financial Officer | 331 0.0014% | $7.58 | $2,509 | +5.96% | |
| 2022-01-26 | Sale | Schoenberg Mark | Chief Medical Officer | 111 0.0005% | $8.09 | $898 | +4.48% | |
| 2022-01-04 | Sale | Barrett Elizabeth A. | Chief Executive Officer | 46,968 0.2096% | $9.15 | $429,757 | -10.38% | |
| 2021-11-30 | Sale | Smith Jason Drew | General Counsel | 3,803 0.0169% | $12.03 | $45,750 | -31.97% |
Insider Historical Profitability
| Schoenberg Mark | Chief Medical Officer | 144284 0.485% | $17.18 | 3 | 27 | <0.0001% |
| Smith Jason Drew | General Counsel | 18824 0.0611% | $17.18 | 1 | 7 | <0.0001% |
| ProQuest Investments IV, L.P. | 10 percent owner | 1242031 4.0317% | $17.18 | 0 | 2 | |
| Barrett Elizabeth A. | Chief Executive Officer | 300985 0.977% | $17.18 | 4 | 2 | <0.0001% |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 10405 0.0338% | $17.18 | 0 | 9 | |
| Mullennix Stephen | Chief Operating Officer | 10084 0.0327% | $17.18 | 0 | 7 | |
| Henderson Molly | Chief Financial Officer | 5248 0.017% | $17.18 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $48.86M | 9.02 | 3.26M | +88.63% | +$22.96M | 0.72 | |
| RA Capital Management, L.P. | $46.25M | 8.53 | 3.08M | 0% | +$0 | 0.05 | |
| Great Point Partners | $39.31M | 7.25 | 2.62M | 0% | +$0 | 6.59 | |
| Menora Mivtachim Holdings Ltd | $34.55M | 6.37 | 2.3M | 0% | +$0 | 0.27 | |
| BlackRock | $25.75M | 4.75 | 1.72M | -0.14% | -$37,365.00 | <0.01 | |
| Cowen Group | $24.4M | 4.5 | 1.63M | New | +$24.4M | 0.77 | |
| Adage Capital Partners Gp L L C | $19.5M | 3.6 | 1.3M | New | +$19.5M | 0.04 | |
| Credit Suisse | $18M | 3.32 | 1.2M | 0% | +$0 | 0.02 | |
| Point72 Asset Management | $16.68M | 3.08 | 1.11M | +782.56% | +$14.79M | 0.03 | |
| Jefferies Financial Group | $12.6M | 2.33 | 840,000 | New | +$12.6M | 0.23 | |
| Migdal Insurance Financial Holdings Ltd | $10.3M | 1.9 | 686,472 | +5.89% | +$572,545.55 | 0.17 | |
| Harel Insurance Investments Financial Services Ltd | $10.1M | 1.86 | 673,487 | -22.59% | -$2.95M | 0.21 | |
| State Street | $8.05M | 1.49 | 536,994 | +9.4% | +$692,445.00 | <0.0001 | |
| Silverarc Capital Management Llc | $7.63M | 1.41 | 508,587 | -3.2% | -$252,255.00 | 2.25 | |
| Wildcat Capital Management | $7.43M | 1.37 | 495,606 | 0% | +$0 | 2.7 | |
| Morgan Stanley | $5.86M | 1.08 | 390,549 | -14.19% | -$968,625.33 | <0.0001 | |
| Geode Capital Management | $4.86M | 0.9 | 323,952 | +3.66% | +$171,540.00 | <0.0001 | |
| Opaleye Management Inc | $4.05M | 0.75 | 270,000 | -15.63% | -$750,000.00 | 0.64 | |
| T. Rowe Price | $4.01M | 0.74 | 267,143 | New | +$4.01M | <0.0001 | |
| Laurion Capital Management LP | $3.76M | 0.69 | 250,600 | 0% | +$0 | 0.11 | |
| Northern Trust | $3.49M | 0.64 | 232,500 | -1.16% | -$41,040.00 | <0.01 | |
| Wells Fargo | $3.18M | 0.59 | 212,280 | -3.1% | -$102,014.52 | <0.01 | |
| The Vanguard Group | $2.92M | 0.54 | 194,966 | +14.28% | +$365,505.00 | <0.0001 | |
| Parkman Healthcare Partners Llc | $2.76M | 0.51 | 184,184 | +4.95% | +$130,260.00 | 0.34 | |
| ARK Investment Management LLC | $2.19M | 0.41 | 146,329 | -9.41% | -$227,940.00 | 0.02 | |
| Alphacentric Advisors Llc | $2.16M | 0.4 | 143,898 | -7.16% | -$166,530.00 | 1.37 | |
| Wellington Management Company | $2.05M | 0.38 | 136,741 | +30.73% | +$482,115.00 | <0.0001 | |
| Goldman Sachs | $1.71M | 0.32 | 113,862 | -0.31% | -$5,385.00 | <0.0001 | |
| Schonfeld Group | $1.56M | 0.29 | 104,100 | -21.08% | -$417,000.00 | 0.01 | |
| Nuveen | $1.25M | 0.23 | 83,419 | 0% | +$0 | <0.0001 | |
| Annandale Capital | $1.22M | 0.23 | 81,552 | -0.34% | -$4,184.04 | 0.35 | |
| Two Sigma | $1.21M | 0.22 | 80,497 | -38.44% | -$753,870.00 | <0.01 | |
| Cibc World Markets Corp | $1.13M | 0.21 | 75,000 | New | +$1.13M | 0.01 | |
| Citadel Advisors LLC | $1.08M | 0.2 | 71,816 | -50.09% | -$1.08M | <0.01 | |
| Ameriprise Financial | $1.06M | 0.2 | 70,952 | -2.75% | -$30,135.00 | <0.0001 | |
| Rice Hall James & Associates, LLC | $1.06M | 0.2 | 70,406 | +0.73% | +$7,710.00 | 0.06 | |
| BNY Mellon | $1.02M | 0.19 | 68,219 | -2.69% | -$28,275.00 | <0.0001 | |
| Charles Schwab | $943,200.00 | 0.17 | 62,880 | 0% | +$0 | <0.0001 | |
| Squarepoint Ops LLC | $945,585.00 | 0.17 | 63,039 | +5.61% | +$50,235.00 | <0.01 | |
| Oak Ridge Investments | $918,060.00 | 0.17 | 61,204 | New | +$918,060.00 | 0.09 | |
| HSBC | $794,310.00 | 0.15 | 52,954 | New | +$794,310.00 | <0.01 | |
| Bank of America | $795,945.00 | 0.15 | 53,063 | -25.96% | -$279,015.00 | <0.0001 | |
| Atom Investors Lp | $746,850.00 | 0.14 | 49,790 | -17.24% | -$155,625.00 | 0.09 | |
| UBS | $643,005.00 | 0.12 | 42,867 | +71% | +$266,970.00 | <0.0001 | |
| AQR Capital | $633,930.00 | 0.12 | 42,262 | +129.9% | +$358,185.00 | <0.01 | |
| Millennium Management LLC | $628,200.00 | 0.12 | 41,880 | -90.18% | -$5.77M | <0.0001 | |
| RhumbLine Advisers | $551,940.00 | 0.1 | 36,796 | +6.02% | +$31,350.00 | <0.01 | |
| Coastal Bridge Advisors Llc | $555,000.00 | 0.1 | 37,000 | -1.99% | -$11,250.00 | 0.13 | |
| Cerity Partners | $554,475.00 | 0.1 | 36,965 | -70.48% | -$1.32M | <0.01 | |
| Meitav Dash Investments Ltd | $551,932.00 | 0.1 | 36,798 | -59.76% | -$819,813.56 | 0.01 |